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Abstract: There is an urgent need for the discovery of new antileishmanial drugs with a new
mechanism of action. Type 2 NADH dehydrogenase from Leishmania infantum (LiNDH2) is an
enzyme of the parasite’s respiratory system, which catalyzes the electron transfer from NADH to
ubiquinone without coupled proton pumping. In previous studies of the related NADH: ubiquinone
oxidoreductase crystal structure from Saccharomyces cerevisiae, two ubiquinone-binding sites (UQI and
UQII) were identified and shown to play an important role in the NDH-2-catalyzed oxidoreduction
reaction. Based on the available structural data, we developed a three-dimensional structural
model of LiNDH2 using homology detection methods and performed an in silico virtual screening
campaign to search for potential inhibitors targeting the LiNDH2 ubiquinone-binding site 1–UQI.
Selected compounds displaying favorable properties in the computational screening experiments
were assayed for inhibitory activity in the structurally similar recombinant NDH-2 from S. aureus
and leishmanicidal activity was determined in the wild-type axenic amastigotes and promastigotes
of L. infantum. The identified compound, a substituted 6-methoxy-quinalidine, showed promising
nanomolar leishmanicidal activity on wild-type axenic promastigotes and amastigotes of L. infantum
and the potential for further development.
Keywords: Leishmania infantum alternative NADH dehydrogenase (LiNDH2); antileishmanial drugs;
Leishmania infantum virtual screening; drug design
1. Introduction
The leishmaniases, classified as neglected tropical diseases, comprise a group of diseases caused by
more than 20 known species of protozoan Leishmania parasites that are usually transmitted to humans
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through bites of infected female phlebotomine sandflies. There are three main forms of leishmaniasis,
described as cutaneous, visceral or kala-azar, and mucocutaneous. The disease predominantly affects
low-income countries with an overall population of 200 million people in Asia, Africa, South and
Central America and is commonly associated with malnutrition, substandard housing conditions,
and lack of resources [1].
The enzyme family of type 2 NADH:quinone oxidoreductases (NDH-2s) is present in various
microorganisms and plants, and a possible variation in humans [2,3]. These enzymes are putative drug
targets for the treatment of parasitic infections such as leishmaniasis as these parasites also present
a NDH-2, LiNDH2 in L. infantum [4]. In general, NDH-2 is a peripheral membrane protein which forms
an intimate dimer, in which packing of the monomeric units within the dimer creates an amphiphilic
membrane–anchor domain structure [5].
The oxidoreduction mechanism of NDH-2 enzymes is explained through the electron transfer
process from soluble NADH via flavin adenine dinucleotide (FAD) to membrane-bound UQ, a catalytic
reaction shown in the top section of Figure 1. In comparison to the type 1 NADH: quinone
oxidoreductase family, the respiratory complex I, which also catalyzes electron transfer reactions
and is ubiquitously present in animals and other species, no proton motive force is observed and the
process of catalysis is irreversible and exergonic [6,7]. The energy of the NDH-2 catalyzed reaction is
released as heat and produced ubiquinol is then reoxidized by other enzymes, such as the alternative
oxidase. This enzyme is directly responsible for a reduction of oxygen, suggesting that both enzymes
are crucial for the sustained respiration cycle of the parasite [8].
Figure 1. Oxidoreduction reaction of NDH-2 enzymes. Cartoon representation of the model structure
of the NDH-2 from L. infantum. The homodimer representation of LiNDH2 homology model generated
using Phyre2 server is presented in a cartoon style. Orientation and structural arrangement of the
monomer units were obtained using 3D alignment with the used template structures (Protein Data Bank
IDs: 4g6g, 4g73 and 5jwa [9,10]). The homodimer consists of reciprocally oriented monomers and is
located on the surface of the mitochondria intermembrane. C-termini are embedded into the membrane
layer (inner mitochondrial membrane). In depicted reaction: NADH/NAD+ denote nicotinamide
adenine dinucleotide protonated/deprotonated; UQ/UQH2 ubiquinone deprotonated/protonated
and FAD flavin adenine dinucleotide.
The enzymatic mechanism of NDH-2s was proposed to follow a two-site ping-pong mechanism,
but recent evidence showed the presence of a ternary complex [11,12]. Two different non-overlapping
pockets for UQ and NADH were reported [6]. Additionally, from the obtained crystal structure
of ScNDH-2, two ubiquinone binding sites (UQI and UQII) were suggested (Figure S2A). A charge
complex between NAD+ and FAD was observed, which was only dissociated by quinone reduction [13].
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Based on available structural data [9], including the observation that the UQI binding site is also
showing a higher percentage of the electron density in comparison with the UQII, and is thus
better defined through crystallographic structure analysis (Figure S2B), UQI appears thus to be more
appropriate for structure-based design studies in search for new NDH-2 inhibitors. Inhibition of the
L. infantum NDH-2 enzyme should cause respiration difficulties and possible parasite elimination [7].
In this study, we have developed a homology model of the LiNDH2 and performed a virtual
screening to search for potential inhibitors against the LiNDH2 targeting UQI. Selected compounds
displaying favorable properties as a result of in silico screening were assayed for their in vitro
inhibitory activity in the available structurally analogous SaNDH2 and their leishmanicidal potential
in L. infantum axenic amastigotes and promastigotes.
2. Results and Discussion
2.1. Construction of the LiNDH2 Homology Model
Due to unavailable crystallographic data on LiNDH2, we used a homology modeling approach
for the generation of the three-dimensional target structure. For this purpose, we utilized
Phyre 2 web-portal v2.0 [14]. The best identified template structures found in the Protein
Data Bank (PDB) were rotenone-insensitive NADH:ubiquinone oxidoreductase from S. cerevisiae
(Chain B, 4g6g or 4g73)—ScNDH2 and NADH:quinone oxidoreductase from S. aureus (Chain C,
4xdb)—SaNDH2 [9,15,16]. The modeling pipeline of Phyre2 web-portal produced a structure with
100% modeling confidence and a score of 33% and 27% identity for ScNDH2 and SaNDH2, respectively,
(Table S1). The modeling confidence suggests that our model is likely to adopt the overall 3D structure,
generated with the Phyre2 pipeline. Also, there is strong evolutionary relatedness between the query
(LiNDH2) and the template structures (ScNDH2 and SaNDH2). Although sequence identity is above
the twilight zone [17], we find that further sequence analysis using primary sequence alignment
methods might lead to more useful data, especially regarding amino acids’ similarity within the UQI
binding pocket which was used in virtual screening. For this purpose, we compared the results of
the Phyre2 alignment method with Clustal alignment, as outlined in Figure 2. The most prominent
template for the LiNDH2 homology model development was ScNDH2, as shown using primary
sequence alignment. The next best template was SaNDH2, and we used both structures in the
development of our homology model which was important for the design of in vitro evaluation.
During the course of writing this paper, another NDH-2–PfNDH2 was submitted to the PDB (5jwa) [10].
We found these data important for sequence alignment purposes and included them in the analysis.
Two conserved regions between residues 50–70 are substrate-binding residues. Motif GxGxxG is
found in each homolog and in our model sequence. Another conserved domain is located between
residues 175–195. These are twisted beta sheets, which are most likely responsible for the FAD binding.
The binding site UQI differs in some extent between LiNDH2 and other NDH-2s. More details are
derived from sequence alignment and summarized in Figure 2.
The main difference between the quinone binding site from LiNDH2 and that of SaNDH2
(and other templates as well) is the lack of the AQxAxQ motif. The two glutamine residues present in
this motif may have a role in quinone binding, as discussed elsewhere [2,13,15]. Overall, the structural
sequence alignment also shows significant percentage of similarity between the active sites of LiNDH2
and PfNDH2. Residues Ser342 and Tyr25 are unique to LiNDH2 sequence, being part of the UQI
binding site. Moreover, the model of LiNDH2 shows higher percentage of hydrophobic residues
in comparison to all template structures and we found this to be the main source of divergence
among NDH-2s. Such an observation has repercussions in formation of the binding hydrophobic
cavity within UQI, namely residues between Arg368–Met373 and Val383–Leu385, thus indicating that
selectivity for inhibitor development could be feasible (Figure S3). The LiNDH2 homology model is
shown schematically in Figure 3. It was further evaluated with the Ramachandran plot (Figure S4),
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structurally aligned and compared to the three-dimensional template structures (root-mean-square
deviation (RMSD) calculations are shown in Table 1).
Figure 2. Sequence alignment of query (model–LiNDH2) and important template sequences: ScNDH2,
PfNDH2 and SaNDH2. Secondary structure prediction within alignment was generated using PSIPRED
v3.3 [18]. For further information regarding secondary structure alignment (SSA), see Figure S1 [19].
Summary in the lower right corner contains the alignment scores between model and each template,
sequence identity and percent similarity (homology). The alignment analysis in the summary is
obtained using Sequence Manipulation Suite [20]. Within summary, numeration of amino acid residues
which create the binding pocket is deduced from sequence alignment and the total binding pocket
similarity was calculated considering just these residues. Li, Leishmania infantum; Sc, Saccharomyces
cerevisiae; Pf, Plasmodium falciparum; Sa, Staphylococcus aureus.
Table 1. Results of the 3D structural alignment between the LiNDH2 homology model and the templates
used—ScNDH2 (4g73) and SaNDH2 (4xdb), RMSD is expressed as all atoms and Cα-chain (backbone).
Root-Mean-Square
Deviation (RMSD) for
Model to 4g73
(No. of Residues and % Aligned)
Model to 4xdb
(No. of Residues and % Aligned)
All atoms 0.227 Å (321 residues, 74% aligned) 2.822 Å (370 residues, 85% aligned)
Cα-chain 0.923 Å (396 residues, 91% aligned) 1.331 Å (252 residues, 58% aligned)
The structure of LiNDH2 contains two Rossmann domains characteristic of two-dinucleotide
binding domains flavoprotein superfamily [2,7,11]. The structure differs in C-terminal domain (CTD)
which is longer for LiNDH2 in comparison to templates, thus insufficiently modelled. The CTD
is responsible for membrane interaction. The number of residues which are located in the favored
region of the Ramachandran plot is 89% which includes 469 of total 527 LiNDH2 amino acid residues.
This result was expected since the long CTD of LiNDH2 could not be modeled efficiently due to lack of
the corresponding homology template sequence. However, none of these missing CTD residues are
close to the target active site, and as such these amino acids are not relevant to our inhibitor design
efforts. The number of LiNDH2 residues in the allowed region is 5.9%, namely 31 residue side chains
are found in unusual places but have acceptable rotamers in case of loop and turn formations. Finally,
the residues in the outlier region are 4.8%, meaning 25 amino acid residues are not correctly modeled.
Since our interest for inhibitor design focused on the well-modeled binding site UQI of LiNDH2,
homology modeling results were considered appropriate for structure-based design.
Molecules 2018, 23, 772 5 of 16
Figure 3. (A) Cartoon representation of the homology structural model of LiNDH2 in two orientations.
Color code: C-terminus to N-terminus (red to blue); Mg2+ ions (green spheres); NADH, flavin adenine
dinucleotide (FAD) and ubiquinone-binding (UQ) molecules are colored by atom element; (B) close up
on UQI (docking data) with flavin group, UQ molecule and residues within 5 Å radius. Interactions
with UQ to FAD, 3.3 Å and UQ to Ser342, 3.4 Å are shown.
2.2. Ligand-Based Pharmacophore Modeling and Virtual Screening
After the generation of the LiNDH2 homology model, we first performed a ligand-based screening.
The ligand-based pharmacophore approach is one of the standard ways to proceed with such large
virtual screening and has been proved to be very efficient [21]. In the absence of the reported
LiNDH2 inhibitors we looked for inhibitors of NDH-2s from other species. We found studies of
hydroxy-2-dodecyl-4-(1H) quinolone (HDQ) derivates showing nanomolar inhibition of NDH-2 from
the malaria-causing microorganism P. falciparum Figure 4A, [22]. These derivatives presented high
chemical similarity to the ubiquinone structural scaffold that interacts with LiNDH2 and so we decided
to test them.
Three molecules from the HDQ series were taken as starting points for further ligand-based
pharmacophore design. We comprised them as a training set and generated 10 ligand-based
pharmacophore models using LigandScout software [23]. We chose to proceed with the two
best-ranked models to increase the coverage of the chemical space that the pharmacophore-based
screening could identify. To increase the chemical space diversity, models were reduced and optimized.
Reduction of the pharmacophore features was performed with the utilization of decoy compounds,
molecules that were assumed to be inactive (see Methods section for further details). This has been
shown to be good standard practice in the screening literature [21]. The optimized ligand-based
pharmacophore model 1 has three hydrophobic elements, one H-donor, one H-acceptor and one
aromatic ring pharmacophore feature, while the selected model 2 possess three hydrophobic features
and two H-acceptors along with one aromatic ring pharmacophore element, as shown in Figure 4B.
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The two final models differ predominantly in 1 pharmacophore feature, namely substituting the
H-donor (model 1) for a H-acceptor (model 2) approximately on the same geometrical position.
The in house prepared library of 500,000 commercially available compounds originating from
different vendors (e.g., VITAS-M, ChemDiv, ChemBridge, etc.) was screened using both models
consecutively, to discard all the compounds which were not able to align to both model’s features.
Virtual screening yielded 4423 hit molecules highly diversified in their chemical structures. In Figure 4C,
an example of a hit compound 15, a 6-methoxy-quinalidine derivate, aligned to both pharmacophore
models, is shown.
Figure 4. (A) Ligand-based similarity between UQ and hydroxy-2-dodecyl-4-(1H) quinolone (HDQ).
Pharmacophore training set based on the selected HDQ derivates with IC50 activity against P. falciparum;
(B) Derived ligand-based pharmacophore models 1 and 2 with aligned HDQ derivatives; (C) Example
of the virtual screening hit compound 15 aligned to the pharmacophore models 1 and 2. Hydrophobic
features are shown as yellow spheres, H-donor as green spheres, H-acceptors as red spheres,
and aromatic feature is colored in blue.
2.3. Molecular Docking of the Pharmacophore-Based Hit Compounds
We evaluated the pharmacophore-based screening hits against the LiNDH2 homology model by
conducting a docking campaign using GOLD docking software [24]. Docking target was LiNDH2 UQI
binding site. First, docking was performed with narrow settings of the GOLD genetic search algorithm
followed by custom genetic algorithm (GA) flexibility settings in order to explore conformational
space within UQI. We reduced the number of hits for further analyses by considering only those hits
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with GoldScore scoring function values between 60–90 as the optimal docking scores for meaningful
docking results [24].
This criterion was satisfied by 54 compounds; for example, for compound 15 the proposed binding
mode in the LiNDH2 UQI binding site is depicted in Figure 5A. The binding mode, shows a formation
of H-bonding with the isoalloxazine ring of FAD and Ser324, which is also observed in the case of UQ.
Furthermore, the chloronapthalen-1-yl-oxyphenyl moiety of compound 15 fills the hydrophobic pocket
(Figure 5A, colored in orange) comprised by a α-helix (Ala397–Leu407) and β-sheet (Gly371–Leu385).
Predicted affinity with GoldScore value of 79.25 is also fully comparable with that of UQ docking,
which scores between 80–84 depending on the conformation of the UQ hydrophobic chain.
Figure 5. Proposed binding modes of the substituted 6-methoxy-quinalidine compound 15 at
(A) LiNDH2 UQI binding site; and (B) SaNDH2 UQ binding site.
Comparison of the crystallographic structure of the UQ binding pose (ScNDH2), re-docked UQ
into template structure (ScNDH2) and docked UQ into the model (LiNDH2), allowed us to explore the
conditions for the docked compounds. First, amide nitrogen of the isoalloxazine ring of FAD acts as
H-donor and should interact with the H-acceptor from the active hit compounds. Second, the hydroxyl
group from the amino acid residue Ser324 should interact with the hit compounds through formation
of a hydrogen bond or OH–pi interaction. In some cases Tyr25, which is positioned close to Ser324,
contributes to the stabilization of the compounds in the binding site mainly through hydrogen bonding.
The hypothesis for the importance of these interactions is further supported by the docking of the UQ
in the mutant models of LiNDH2 without Ser324 and Tyr25, (Figure S5). Finally, hit compounds should
fill the hydrophobic pocket formed between α-helix (Ala397–Leu407) and β-sheet (Gly371–Leu385).
These guidelines were used to predict potential interactions and to reduce the number of selected
hit compounds.
We further assumed that docking poses in LiNDH2 UQI binding site should align with proposed
pharmacophore model features in regards to orientation and position in the binding site. It was
gratifying to observe that the majority of docked conformations of the selected compounds strongly
resembled the alignment with pharmacophore-based models, pointing to specific ligand-protein
interactions (see Figure S6, example with compound 15). Also, we considered diversity among scaffolds
for further testing and excluded potential pan-assay interference compounds (PAINS) [25]. In the
final compound selection, we also considered pharmacophore scoring function values of compounds
aligned to our pharmacophore (PharmFit), used GoldScore scoring function values for docking modes
and a geometrical consensus between the pharmacophore fitting of hits to the pharmacophore models
and docking binding modes in the LiNDH2 UQI binding site (see Table S2 for score values). Finally,
we selected 23, chemically very diverse hit compounds for experimental testing (Table 2). Sources of
all commercially available compounds are provided in supplementary information Table S3.
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Table 2. Results of the inhibition assays of the selected hit compounds 1–23 derived from the virtual screening campaign against LiNDH2, expressed as relative activity
(RA) of the NDH-2 from S. aureus. RAs in % at 20 µM compound concentration were calculated considering the activity in the absence of any inhibitor as 100%.
Compd. Chemical Structure RA Compd. Chemical Structure RA Compd. Chemical Structure RA
1 93% 9 80% 17 91%
2 75% 10 92% 18 86%
3 71% 11 83% 19 92%
4 74% 12 95% 20 84%
5 86% 13 86% 21 94%
6 89% 14 93% 22 86%
7 86% 15 49% 23 88%
8 99% 16 87%
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2.4. Results of the In Vitro Inhibition Assays and Measurements of the Leishmanicidal Effect
Selected compounds were first assayed for their in vitro inhibition activity in the structurally
similar recombinant NDH-2 from S. aureus (SaNDH2), since isolated LiNDH2 was not available. Most of
the selected compounds covering a large conformational space showed only negligible inhibition
activity (Table 2). This reflects the complex nature of the ligand–protein molecular recognition process
that poses challenges to full explanation due to lack of data, known limitations in screening models,
and diversity among enzymes.
Nevertheless, compound 15, a substituted 6-methoxy-quinalidine, did show promising inhibition
results for SaNDH2 in the initial screening with the RA value of 49% measured at 20 µM.
Binding modes of the hit compound 15 to SaNDH2 and LiNDH2 both show H-bonds with FAD
and, additionally, interaction with Thr48 side chain is recorded in case of SaNDH2 binding (Figure 5B).
Alternative conformations of the 6-methoxy-quinalidine scaffold pose are observed among the docking
results. This indicates that the mechanism of binding for compound 15 as a general NDH-2 inhibitor is
debatable, although correct according to the binding hypothesis. Encouraged by this positive result,
we preceded with Kiapp determination using steady-state analyses which resulted in the 8.9 ± 1.0 µM
value. This classifies compound 15 as a promising hit due to its low micromolar range inhibition
activity (Figure 6). It should be noted that for compound 15 anti-malarial activity was previously
reported [26–28].
Figure 6. Steady-state analyses of the activity of NDH-2 from S. aureus in the presence of compound 15.
We were further interested to know how much the compounds could influence the growth
of the L. infantum parasite. Two randomly selected inactive compounds from the in vitro enzyme
inhibition assay, compounds 11, 20 along with the active compound 15, were selected to assay their
leishmanicidal activity over wild-type L. infantum axenic amastigotes and promastigotes. The selection
of inactive compounds was done also to probe whether the observed inactivity at the in vitro level
would be noticed at the level of the leishmanicidal determination. Graphs of the compound’s typically
observed leishmanicidal effect in the wild-type axenic proamastigotes and amastigote cultures for the
hit compound 15 are shown in Figure 7.
Only compound 15 that showed strong in vitro inhibition of the NDH-2 enzyme (SaNDH2) also
possessed leishmanicidal activity with the potent IC50 values in the interval between 0.03–0.05 µM
against promastigotes and in the interval between 0.2–0.3 µM against amastigotes of L. infantum
(Table 3 and Figure 7). Interestingly, compound 15 in previous investigations of leishmanicidal activity
against transgenic Leishmania mexicana promastigotes that were glucose-transport deficient also showed
some potential [29]. Thus, compound 15 displays itself as a promising starting point for further
development of potent agents against Leismania infantum parasites. One important additional aspect
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that will have to be evaluated in further development of this hit compound is also to determine its
influence on the mammalian cells [30].
Figure 7. Concetration-dependant leishmanicidal effect in wild type axenic (A) proamastigotes and
(B) amastigotes in L. infantum cultures for compound 15.
Table 3. Results of the leishmanicidal effect measurement of selected hit compounds in the wild-type
axenic amastigotes and promastigotes of L. infantum.
Compound Wild Type IC50 (µM)
Promastigotes Amastigotes
11 5–10 >20
15 0.03–0.05 0.2–0.3
20 5–10 >20
Provided intervals are results of three independent measurements.
3. Materials and Methods
3.1. Construction of the LiNDH2 Homology Model
Protein homology/analogy recognition engine [14], Phyre 2 (v2.0) provided a possibility for
the LiNDH2 template proteins’ identification and homology modelling in order to carry out rational
structure-based design in search for novel inhibitors in the absence of the LiNDH2 crystal structure.
The sequence of LiNDH2 found under entry A4IDV2 from UniProt web server [31], was used as
a query to Phyre 2 server with normal modelling mode. The best template structures identified
were ScNADH:ubiquinone oxidoreductase (Chain B, PDB: 4g6g or 4g73) and SaNADH:quinone
oxidoreductase (Chain C, PDB: 4xdb) with 33% and 27% identity, respectively, and 100% modelling
confidence [9,15,16]. The template sequences, ScNDH2 (P32340), PfNDH2 (Q8I302) and SaNDH2
(Q2FZV7) were retrieved for alignment purposes. The sequence alignment was generated using
Clustal X software and comparison between sequences of corresponding structures was done via
Sequence Manipulation Suite which provided sequence similarity and homology similarity between
templates and LiNDH2 query sequence [20,32]. This was done afterwards to further explore amino
acid sequence similarities due to automatic template utilization using the Phyre 2 server. Furthermore,
the homology model was evaluated using the RAMPAGE tool through generation of a Ramachandran
plot [33]. For additional information regarding the homology model using Ramachandran plot, see the
supplementary material (Figure S4).
The structure of ScNDH2 (PDB ID 4g73) was downloaded and prepared for the analysis of
the crystallographic UQ binding site. Pymol software was used to remove undesired components
(“A” chain, crystal waters, other molecular residues) except chain “B”, containing UQ, FAD, NADH
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and Mg2+ metal ions. Crystallographic structural data was used for the extraction of FAD, NADH and
UQ conformations and poses in order to set up docking parameters with evaluation of re-docking
results using RMSD.
3.2. Alignment of Protein 3D Structures
We aligned the LiNDH2 homology model and two templates using pymol software [34].
Both templates: (1) ScNDH2 (PDB ID 4g73) and (2) SaNDH2 (PDB ID 4xdb) were downloaded
into pymol and cleaned through removal of non-protein atoms and chains until mono units were
obtained. Afterwards, we optimized the CTD of the LiNDH2 homology model for alignment purposes
by truncating it at residue 436 (Table S1). RMSD values were calculated along the alignment in two
steps: (1) RMS for all atoms and (2) RMSD for the C-backbone only. Not all of the residues were
aligned and certain gaps were observed; thus the final alignment was calculated in percentages of
total 436 residues of the model (with 436 being considered as 100%). The results are summarized in
Table 1. Three-dimensional structural alignment was used to generate molecular data (system size,
conformations and position of cofactor and ligands) needed for structure-based design.
3.3. Ligand-Based Pharmacophore Modeling and Virtual Screening
Ligand-based pharmacophore modeling and virtual screening were performed using
LigandScout [23]. The ligand-based pharmacophore models were built using available data of the
selected HDQ derivatives with nanomolar inhibition activity on NDH-2 from the malaria-causing
microorganism P. falciparum. Using ChemDraw, we draw the 2D structures of three selected HDQ
derivatives [35]. We optimized and minimized their three-dimensional structures in LigandScout’s
implemented MMFF94 force field, and imported them into the ligand-based module within
LigandScout for ligand-based pharmacophore generation.
Parameters for the LB conformer generator in OMEGA software were set to obtain 500 unique
conformations for each of the active compounds. The RMS threshold for duplicate conformers was
set to 0.4 Å, the maximum number of all generated conformers per molecule to 30,000, and the
maximum number of intermediate conformers per molecule to 4000 [36]. The conformations were
then dynamically aligned yielding 10 final ligand-based merged pharmacophore models. We used
the LigandScout inbuilt scoring function that combined pharmacophore fit and atom shape overlap
in order to assess the models produced. The LB pharmacophore models with the highest score of
0.911 and 0.910 were selected for further use, Figure 4B,C.
For the chemical space diversity search and recognition patterns, our chosen pharmacophore
models were optimized in a number of available merged pharmacophore features. The discriminatory
performance of the derived pharmacophore models was validated by a screening experiment against
150 decoys (50 per selected active compound) using a Database of Useful Decoys: Enhanced (DUD-E
server) [37]. Decoys were generated by introducing SMILES of active compounds as template
molecules into DUD-E server. Decoys have similar physical properties but different chemical
structures, which is defined by the maximum Tanimoto value threshold between active compound
and decoy molecule MACCS fingerprints [37]. The decoys were employed in small benchmarking
screening procedures over a total of 10,000 compounds from home libraries with potential activity.
Pharmacophore models were run in a subsequent manner. Screening with model 1 coupled with
subsequent screening with model 2 reported 24/150 decoys in the first cycle run. When the reduction
and modification of pharmacophore features in model 1 and 2 took place, identical screening
procedure yielded 3/150 decoys among a final training set of 1186 potential hits. The purpose
of this training method was to optimize the number of pharmacophore features of the models in the
lack of known LiNDH2 active compounds. The reduced ligand-based pharmacophore models were
used in the virtual screening process. The number of compounds in the used virtual library was
approximately 550,000. Screening libraries contained commercially available compounds converted
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into the multifunctional format, 25 conformations for each compound in the library. The screening
algorithm took approximately 17 h to complete.
3.4. Molecular Docking Calculations
For molecular docking purposes, we used a standard GOLD docking program coupled with the
GoldScore fitness function [24]. Docking calculations were performed in the presence of FAD and
NADH that we modeled in the LiNDH2. Cofactor and substrate structures were obtained from PDB
4g73 prior to the docking calculation after 3D structural alignment. We first optimized docking settings
by docking the UQ molecule into template structures ScNDH2 and SaNDH2. Then, we docked the UQ
LiNDH2 homology model in order to assess the docking performance and compare the UQ posing
results with the crystallographic data. Protein structures were prepared in mol file format as suggested
in the GOLD manual [24]. The following settings were used: defined binding site as all atoms within
6 Å of the crystallographic UQ, that is within the UQI binding site, and we defined a constraint of 3.5 Å
between residues Leu444 and Leu447 of the pdb ID 4g73 structure. This constraint gave an additional
score for the flexible hydrophobic moiety of UQ, which is observable in the crystallographic ligand pose
in the template (4g73). We used the same settings for the docking of UQ in the SaNDH2 and LiNDH2
models with a constraint within the hydrophobic cavity (for the homology model, the constraint
sphere encompasses the residues between Arg368–Met373 and Val383–Leu385). The following docking
experiments were performed: (1) redocking of the UQ molecule into the template structure (PDB ID
4g73); (2) docking of UQ into the SaNDH2 template structure (PDB ID 4xdb); (3) docking of UQ,
active compounds (HDQ derivatives used for ligand-based pharmacophore design); and (4) docking
of hit compounds obtained from pharmacophore-based virtual screening into the LiNDH2 model UQI
binding site. Docking procedures (1), (2) and (3) were carried out using the GA with 120% search
efficiency. We calculated the RMSD between the crystal UQ (4g73), re-docked UQ (4g73) and UQ
docked into the LiNDH2 model. The calculated average RMSD of the UQ’s aromatic core between
crystallographic and multiple docked UQ poses was 1.740 Å and an average GoldScore of 82.8 was
obtained. (Table S4).
Docking evaluation (d) of 4423 pharmacophore-based screening hit compounds was done
subsequently, using the GA of GOLD with virtual screening settings, a cut-off set to 50 and a maximum
number of conformations per molecule equal to 3. We obtained 13,041 docking conformations
out of these pharmacophore-based hits which were visualized and evaluated using LigandScout.
Subsequently, the best 428 hits were re-docked using the GA algorithm with 120% search efficiency
(flexible settings). Poses having docking GoldScore between 60–90 (presumed as optimal scoring
function values) were kept and were visually examined and compared to the UQ docking reference.
A total of 54 hits (318 conformations) were submitted for final filtering and selection (see Results and
Discussion section) for activity evaluation. These 54 hits were also docked to SaNDH2 using AutoDock
Vina with exhaustiveness = 100, maximum number of docking modes = 10, and maximum energy
difference = 3 prior to experimental testing on SaNDH2 [38].
3.5. Steady-State Kinetics Experiments to Determine Inhibition Activity of NDH-2 from S. aureus
NADH was purchased from Sigma Aldrich. 2,3-Dimethyl1,4-naphthoquinone (DMN) was
synthesized from menadione (Sigma Aldrich, St. Louis, MO, USA) [39]. In order to test the effect of the
studied compounds 1–23, activity assays were performed on a Shimadzu UV-1800 spectrophotometer
monitoring the change in absorbance of the electron donor, NADH, at 340 nm [15]. The activity
assays were made inside an anaerobic chamber at 35 ◦C, using DMN as electron acceptor. The NADH
extinction coefficient of 6.22 mM−1 cm−1 was used to calculate NDH-2 specific activity (µmol−1 min−1
mg protein). The reaction mixture (1000 µL) contained 20 nM NDH-2 in 100 mM potassium phosphate
pH 7.0, 250 µM NaCl, 100 µM NADH, 150 µM DMN and the tested compounds were added to the
reaction mixture at the final concentration of 20 µM. Residual activity (RA) values were calculated
by using the determined NDH-2 activity at the investigated inhibitor concentration divided by the
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NDH-2 activity determined in the absence of the inhibitor. For compound 15, the Ki determination was
performed at the following concentrations, 50 µM, 20 µM, 10 µM and 5 µM, using the same procedure
described. The obtained data points were fitted using equation:
vi0 = v
max
0
(
1+ β [l]
Kappi
)
(
1+ [l]
Kappi
) (1)
to calculate the apparent Kiapp of 8.9 ± 1.0 µM.
3.6. Determination of Selected Compound Leishmanicidal Effect in Axenic Amastigotes of L. infantum
L. infantum promastigotes (MHOM MA67ITMAP263) were cultured at 25 ◦C in RPMI 1640
Glutamax supplemented with 10% (v/v) inactivated fetal bovine serum (iFBS), 50 U mL−1
penicillin, 50 mg mL−1 streptomycin (from Gibco) and 25 mM HEPES sodium salt pH 7.4 (Sigma).
Axenic amastigotes of L. infantum were grown at 37 ◦C and 5% CO2, in MAA medium supplemented
with 20% (v/v) iFBS, 2 mM Glutamax (GibcoBRL), and 0.023 µM hemin (Sigma), as described
previously [40]. Parasites were seeded at 1.5 × 106 cells mL−1 in 96-well plates in complete
MAA20 medium for amastigotes and RPMI for promastigotes with varying concentrations of the
different compounds. Twenty-four hours later, parasite viability was measured by the resazurin
assay and calculated as the percentage in relation to control cultures incubated with the vehicle
alone, as described [41]. Data were analyzed and half-maximal inhibitory concentration (IC50)
values determined.
4. Conclusions
There is an urgent need for new antileishmanial drugs with alternative unexploited mechanisms
of action for tackling widespread leishmaniases. Alternative NADH dehydrogenase from L. infantum is
an important new target, its inhibition expecting to cause respiration difficulties leading to the possible
elimination of the targeted parasite [4]. Based on the available structural data from NDH-2s from
S. cerevisiae and S. aureus, we developed and validated a three-dimensional homology model of the
L. infantum NDH-2. Then, ligand-based pharmacophore models and virtual screening, using reported
4-quinolone inhibitors of NDH-2 from P. falciparum, were coupled with subsequent molecular-docking
calculations, which resulted in 54 hits with an inhibitory potential. Twenty-three compounds displaying
a consensus of docking scores were selected, and pharmacophore fit scores and visual binding modes
were assayed for their in vitro inhibitory activity towards recombinant NDH-2 from S. aureus and
their leishmanicidal activity for L. infantum axenic amastigotes and proamastigotes. Our experimental
results identified 6-methoxy-quinalidine as an inhibitor of NDH-2 from S. aureus (Kiapp = 8.9 ± 1.0 µM).
This compound also exhibits a promising leishmanicidal effect in the nanomolar range in wild-type
axenic amastigotes (IC50 interval between 200–300 nM) and promastigotes (IC50 interval between
30–50 nM) rendering it of potential interest for further development and optimization. Our combined
results comprise a valuable step towards the discovery of resistance-free NDH-2 inhibitors and
the resulting compound 15 could serve as a starting point in developing a potent drug against
Leismania infantum parasites.
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